A drug repositioning case from Pfizer is getting the attention from the pharma industry. A drug that was initially intended to treat HIV has presented positive perspectives to be repurposed for the treatment of deadly consequences of bone marrow transplants used to tread blood cancers like leukemia, myeloma and lymphoma.
The drug – Selzentry – that failed as to treat HIV went through a small clinical trial with 38 patients, which study can be seen at the New England Journal of Medicine , was already on the market and now will go through large clinical trials to confirm its results and be set to prevent the graft-versus-host-disease.
If successful, Pfizer's Selzentry repurposing case can be an exemplar one, as it shows the great economic value of approaching drug repositioning and will probably help pharma to understand how to potentially streamline the process of finding new therapeutic uses for existing molecules. The opportunity lies on saving billions of dollars worth of R&D to find new drugs for particular diseases, and change the perception of drug repositioning by pharma as to start considering multiple targets for every drug, instead of the opposite.
At the World Drug Repositioning Congress USA 2012 – Washington, D.C., December 4th and 5th – this and other drug repurposing case studies, approaches and technologies will be presented by leaders from pharma, government, biotechs, biotech and academia, to discuss the streamline potential of repurposing drugs and how does multi-stakeholders collaboration is supporting it.
Read the full article here.